Navigation Links
Poniard Pharmaceuticals to Present New Data from Phase 2 Clinical Trials of Picoplatin in Multiple Tumor Types at the 45th Annual Meeting of the American Society of Clinical Oncology

- Progression-Free Survival Data to be Presented for Phase 2 Colorectal and Prostate Trials -

- Company to Hold Investor Event on Sunday, May 31 with Oncology Experts -

SOUTH SAN FRANCISCO, Calif., May 4 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD) today announced that the Company will present new data from two ongoing Phase 2 clinical trials of picoplatin, the Company's lead product candidate, at poster sessions during the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Orlando. The Company will present results of picoplatin plus docetaxel/prednisone in patients with metastatic castration-resistant (hormone-refractory) prostate cancer (CRPC) and picoplatin plus 5-FU/leucovorin in patients with metastatic colorectal cancer (CRC).

Both presentations will include new, recently obtained, efficacy and safety data, including progression-free survival data, not reflected in the abstracts that will be posted on the ASCO Web site on Thursday, May 14 at 6:00 p.m. Eastern Time. The CRC presentation will be followed by an ASCO poster discussion.

Poster presentation details are as follows:

    --  Results of a Phase II study of picoplatin with docetaxel and
        prednisone in first-line treatment of castration-resistant prostate
        Abstract #5140
        R. De Jager, L. Roman, N. Lopatkin, P. Karlov, H. Breitz, R. Earhart
        General Poster Session: Sunday, May 31, from 2:00 p.m.-6:00 p.m.
         Eastern Time
        Level 2, West Hall C, Poster #J6

    --  Randomized Phase II study of picoplatin in combination with
        5-fluorouracil and leucovorin (FOLPI) as a neuropathy-sparing
        alternative to modified FOLFOX-6 as first-line therapy for colorectal
        Abstract #4026
        R. Earhart, S. Cheporov, O. Gladkov, M. Biakhov, H. Breitz, R. De
        General Poster Session: Monday, June 1, from 8:00 a.m.-12:00 p.m.
         Eastern Time
        Level 2, West Hall E1, Poster #17
        ASCO Poster Discussion: Monday, June 1, from 11:00 a.m.-12:00 p.m.
         Eastern Time, Level 2, West Hall E1

Poniard Investor Event

In addition to the picoplatin posters and presentation, Poniard will host an investor event, in Orlando, on Sunday, May 31, 2009. Presentations will begin promptly at 6:00 p.m. Eastern Time. The event will feature presentations and discussion with expert oncologists, including Richard Goldberg, M.D., of the University of North Carolina's Lineberger Comprehensive Cancer Center, William Oh, M.D. of Harvard Medical School and David S. Ettinger, M.D. of the Kimmel Comprehensive Cancer Center at Johns Hopkins in addition to members of Poniard's senior management team. For more information or to RSVP to the event, please email

About Prostate Cancer

More than 1 million American men are currently living with prostate cancer and it is the second leading cause of death among men in the U.S. In 2008, an estimated 186,320 new cases of prostate cancer were expected to be diagnosed in the U.S., with an estimated 28,660 deaths (American Cancer Society, Cancer Facts and Figures 2009). CRPC is prostate cancer that continues to grow despite current standard of care hormonal (anti-androgen) therapies. CRPC is more invasive and more likely to spread to other organs than androgen dependent prostate cancers. Patients with CRPC have few treatment options and a poor prognosis.

About Colorectal Cancer

CRC is the third most common cancer in both American men and women, and the third leading cause of cancer death in the U.S. In 2009, an estimated 148,810 new cases of colon and rectal cancer were expected to be diagnosed in the U.S., with an estimated 49,960 deaths (American Cancer Society, Cancer Facts and Figures 2009). The current standard of care is associated with significant side effects including neuropathy, which can limit its use and result in its discontinuation. Effective first-line, neuropathy sparing treatment for CRC is a major unmet medical need.

About Picoplatin

Picoplatin is designed to overcome platinum resistance associated with chemotherapy in solid tumors. Study data to date suggest that it has an improved safety profile relative to existing platinum-based cancer therapies. More than 1,100 patients have received picoplatin. Results obtained to date suggest manageable hematologic adverse events with less severe kidney toxicity (nephrotoxicity) and nerve toxicity (neurotoxicity) than is commonly observed with other platinum chemotherapy drugs. Picoplatin has demonstrated anti-tumor activity in a variety of solid tumors. It is being studied in multiple cancer indications, treatment combinations and by two routes of administration.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc., is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead platform product candidate, is a new generation platinum chemotherapy. Clinical trials of intravenous picoplatin include a Phase 3 trial in small cell lung cancer and Phase 2 trials in metastatic colorectal and castration-resistant (hormone refractory) prostate cancers. The Company also is conducting a clinical trial of oral picoplatin in solid tumors. For additional information please visit

(C) 2009 Poniard Pharmaceuticals, Inc. All Rights Reserved.

Poniard and Poniard Pharmaceuticals are trademarks of Poniard Pharmaceuticals, Inc.

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
2. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
3. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
5. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
6. Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
7. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
8. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
9. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
10. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
11. Poniard Pharmaceuticals Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial
Post Your Comments:
(Date:12/1/2015)... 01, 2015 ... the "Medium Molecular Weight Polyisobutylene Market ... Other Applications - Global Industry Analysis, Size, ... 2023" report to their offering. ... addition of the "Medium Molecular Weight ...
(Date:12/1/2015)... 1, 2015   Nottingham Spirk , a ... the publication of a free whitepaper , ... Market". The whitepaper gives medical product companies, pharmaceutical ... this lucrative segment. Nottingham Spirk ... manage their own health, save money (i.e., fewer ...
(Date:12/1/2015)... 1, 2015 Array BioPharma Inc. ... its Chief Executive Officer, Ron Squarer ... Healthcare Conference in New York.  The public ... through a webcast on the Array BioPharma ... --> , ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... 01, 2015 , ... Trustify is proud to announce the success of the ... an organization dedicated to ending domestic violence. , Trustify and Becky’s Fund have joined ... survivors of domestic violence. Trustify is also proud to announce the launch of the ...
(Date:12/1/2015)... ... December 01, 2015 , ... Henderson, a town of ... Gigabit Internet through a partnership this year with Aeneas Internet and Telephone. , ... attractive destination for entrepreneurs who want to build a business. Whether startups or ...
(Date:12/1/2015)... Angeles, CA (PRWEB) , ... December 01, 2015 , ... ... coalition of obesity groups has filed a discrimination claim against the U.S. Department of ... coverage in their Affordable Care Act (ACA) plans are breaking the clause in the ...
(Date:12/1/2015)... ... December 01, 2015 , ... Speech and physical therapies are ... innovative technologies and under the right circumstances, these practices can be merged. ... dual-approach to his or her therapeutic sessions, as well as gives the physical ...
(Date:12/1/2015)... , ... December 01, 2015 , ... It’s official: Tattoo ... tattoo — a number even greater among Millennials (a whopping one in three aged ... and more people who are dissatisfied with their ink. In fact, RealSelf , ...
Breaking Medicine News(10 mins):